XenoPort, Inc. Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 4
Founded: Santa Clara CA United States (1999)
Status: Acquired by Arbor Pharmaceuticals (2015) → now Azurity (2021)

Organization Overview

First Clinical Trial
2005
NCT00838396
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Xenoport